CVMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
CEL SCI CORP
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.65−0.14 (-7.82%)
Close on Oct 19, 2026
- Market cap
- $19.99M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 423.1% | -243.4% | -176.3% | |
| Return on assets | -43.1% | -88.8% | -92.2% | |
| Current ratio | 1.36 | 4.15 | 2.26 | |
| Interest coverage | – | -24.2× | -38.2× | |
| Diluted shares | 0M | 1M | 4M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cel Sci generated $95.81M from operations and spent $10.15M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$95.81M
Used
$10.15M
Capital expenditure$10.15M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$25.41M
- Cash generatingOperating cash flow above zero-$17.12M
- Return on assets improvedROA up on the prior year-88.2% → -94.1%
- Earnings backed by cashOperating cash flow above net income-$17.12M vs -$25.41M
- Less leverageLong-term debt to assets fell– → 20.2%
- Better liquidityCurrent ratio rose1.31 → 2.26
- No dilutionShare count did not rise2M → 4M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –